natgillin/translations-raw huggingface dataset:
The medicine has been shown to be at least as effective as warfarin in reducing stroke rates in patients with atrial fibrillation and in preventing further episodes of DVT or pulmonary embolism. 
Dokazali so, da je zdravilo vsaj tako učinkovito kot varfarin pri zmanjševanju deleža možganske kapi pri bolnikih z atrijsko fibrilacijo in pri preprečevanju nadaljnjih ponovitev globoke venske tromboze ali pljučne embolije.
How is Roteas used? 
Kako se zdravilo Roteas uporablja?
Roteas contains the active substance edoxaban. 
Zdravilo Roteas vsebuje zdravilno učinkovino edoksaban.
Roteas has been shown to be as effective as the standard anticoagulant warfarin in preventing stroke and systemic embolism in patients with atrial fibrillation. 
Izkazalo se je, da je zdravilo Roteas pri preprečevanju možganske kapi in sistemske embolije pri bolnikih z atrijsko fibrilacijo enako učinkovito kot standardni antikoagulant varfarin.
How does Roteas work? 
Kako zdravilo Roteas deluje?
In the treatment and prevention of blood clots in patients with DVT or pulmonary embolism, Roteas was also found to be as effective as warfarin, in a study involving over 8,200 patients. 
V študiji, v kateri je sodelovalo več kot 8 200 bolnikov, so ugotovili, da je zdravilo Roteas enako učinkovito kot varfarin tudi pri zdravljenju in preprečevanju krvnih strdkov pri bolnikih z globoko vensko trombozo ali pljučno embolijo.
or vice versa. 
in obratno.
per day as described above. 
na dan, kot je opisano zgoraj.
Very rare, not known* 
Zelo redki, neznani*
Thus, the results from this subset are in line with the overall trial results. 
Rezultati te podskupine se torej ujemajo s celotnimi rezultati preizkušanja.
The median follow-up for both groups was 359 days. 
Mediano spremljanje je v obeh skupinah trajalo 359 dni.
Children and adolescents Do not give this medicine to children because it does not work. 
Otroci in mladostniki Ne dajajte tega zdravila otrokom ali mladostnikom, ker ne deluje.
Do not stop the treatment unless your doctor tells you so. 
Ne prekinite zdravljenja razen, če tako odloči zdravnik.
• You should tell your doctor if a surgery (including dental) is planned. 
: - morate zdravniku povedati, če imate predvideno kakšno operacijo (tudi zobozdravstveni poseg).
Date of first authorisation: 21 September 2009 Date of latest renewal: 3 June 2014 
Datum prve odobritve: 21. september 2009 Datum zadnjega podaljšanja:
The characteristics of the studied cohort were similar in the 2 groups. 
Značilnosti proučevane kohorte so bile v obeh skupinah podobne.
• Your doctor may order blood tests. 
- lahko vaš zdravnik naroči krvne preiskave.
The requirements for submission of (PSURs) reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal. 
Zahteve glede predložitve PSUR za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES, in vseh kasnejših posodobitvah, objavljenih na evropskem spletnem portalu o zdravilih.
• If you are allergic to clopidogrel or any of the other ingredients of this medicine (listed in section 6). 
- če ste alergični na klopidogrel ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
An occasional use of acetylsalicylic acid (no more than 1000 mg in any 24 hour period), should generally not cause a problem, but prolonged use in other circumstances should be discussed with your doctor. 
Priložnostna uporaba acetilsalicilne kisline (ne več kot 1000 mg v kateremkoli 24-urnem obdobju) na splošno ne bi smela povzročati težav,vendar pa se morate o daljši uporabi v drugih okoliščinah posvetovati s svojim zdravnikom.
The patient population included 41.8 % women. 
V populaciji bolnikov je bilo 41,8 % žensk.
Clopidogrel has been evaluated for safety in more than 44,000 patients who have participated in clinical studies, including over 12,000 patients treated for 1 year or more. 
Varnost klopidogrela so vrednotili pri več kot 44.000 bolnikih, ki so sodelovali v kliničnih študijah, vključno z več kot 12.000 bolniki, ki so se zdravili 1 leto ali več.
Since higher doses of ASA were associated with higher bleeding risk it is recommended that the dose of ASA should not be higher than 100 mg. 
Ker so veliki odmerki ASA povezani s povečanim tveganjem za krvavitve, se priporoča, da odmerek ASA ni večji od 100 mg.
Do not take a double dose to make up for a forgotten tablet. 
Ne jemljite dvojnega odmerka, da bi nadomestili posamezno izpuščeno tableto.
9/l); requirement for clopidogrel or oral anticoagulants (OAC); or intolerance to any of the two compounds. 
9/l), potreba po klopidogrelu ali peroralnih antikoagulantih ali intoleranca za katero od obeh snovi.
for as long as your doctor continues to prescribe it. 
morate jemati, dokler vam ga vaš zdravnik predpisuje.
Clopidogrel has no or negligible influence on the ability to drive and use machines. 
Klopidogrel nima ali ima zanemarljiv vpliv na sposobnost za vožnjo in upravljanje strojev.
The ACTIVE-A study included patients who could not receive VKA therapy because they were unable or unwilling to receive the treatment. 
Študija ACTIVE-A pa je vključila bolnike, ki niso mogli prejemati zdravljenja z VKA, ker zanj niso bili primerni ali ga niso želeli.
No special requirements for disposal. 
Ni posebnih zahtev.
may be taken with or without food. 
lahko jemljete s hrano ali brez nje.
Although the ischaemic benefit was consistent throughout the first year, greater reduction in ischaemic recurrence after ACS was observed during the initial days following the treatment initiation. 
Čeprav je bila korist glede ishemije stalna v celotnem prvem letu, so večje zmanjšanje ishemičnih ponovitev po AKS opažali v prvih dneh po začetku zdravljenja.
The mean CHADS2 score was 2.0 (range 0-6). 
Povprečna ocena CHADS2 je bila 2,0 (razpon: od 0 do 6).
Secondary prevention of atherothrombotic events Clopidogrel is indicated in: 
Sekundarno preprečevanje aterotrombotičnih dogodkov Klopidogrel je indiciran pri:
Medicinal products associated with bleeding risk: There is an increased risk of bleeding due to the potential additive effect. 
Zdravila, povezana s tveganjem za krvavitve: Obstaja večje tveganje za krvavitve zaradi možnega aditivnega učinka.
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. 
Pred začetkom jemanja zdravilanatančno preberite navodilo, ker vsebuje za vas pomembne podatke!
is and what it is used for 
in za kaj ga uporabljamo
Patients were treated for up to one year. 
Zdravili so se do eno leto.
A number of other clinical studies have been conducted with clopidogrel and other concomitant medicinal products to investigate the potential for pharmacodynamic and pharmacokinetic interactions. 
Številne druge klinične študije so izvedli s klopidogrelom in drugimi sočasno danimi zdravili, da bi proučili potencial za farmakodinamične in farmakokinetične interakcije.
All patients were continued on aspirin and were followed for one year. 
Vsi bolniki so še naprej jemali acetilsalicilno kislino in spremljali so jih eno leto.
(1/100 to <1/10); uncommon (1/1,000 to <1/100); rare (1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data). 
Njihova pogostnost je navedena po naslednjem dogovoru: pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
TOPIC and TROPICAL-ACS were designed to study how to mitigate the bleeding events while maintaining efficacy. 
Študiji TOPIC in TROPICAL-ACS sta bili načrtovani za proučitev, kako ublažiti krvavitve in ohraniti učinkovitost.
• Adults and elderly 
Odmerjanje - Odrasli in starejši bolniki
The mean age was 71 years, 41.6% of patients were ≥75 years. 
Povprečna starost je bila 71 let, 41,6 % bolnikov je bilo starih ≥ 75 let.
In cases of confirmed isolated activated Partial Thromboplastin Time (aPTT) prolongation with or without bleeding, acquired haemophilia should be considered. 
V primeru potrjenega izoliranega podaljšanja aktiviranega parcialnega tromboplastičnega časa (aPTČ) s krvavitvami ali brez njih, je treba pomisliti na pridobljeno hemofilijo.
7 film-coated tablets 14 film-coated tablets 28 film-coated tablets 30 film-coated tablets 50 film-coated tablets 56 film-coated tablets 84 film-coated tablets 90 film-coated tablets 100 film-coated tablets 
7 filmsko obloženih tablet 14 filmsko obloženih tablet 28 filmsko obloženih tablet 30 filmsko obloženih tablet 50 filmsko obloženih tablet 56 filmsko obloženih tablet 84 filmsko obloženih tablet 90 filmsko obloženih tablet 100 filmsko obloženih tablet
7 film-coated tablets: EU/1/09/562/001 14 film-coated tablets: EU/1/09/562/002 28 film-coated tablets: EU/1/09/562/003 30 film-coated tablets: EU/1/09/562/004 50 film-coated tablets: EU/1/09/562/005 56 film-coated tablets: EU/1/09/562/006 84 film-coated tablets: EU/1/09/562/007 90 film-coated tablets: EU/1/09/562/008 100 film-coated tablets: EU/1/09/562/009 
7 filmsko obloženih tablet: EU/1/09/562/001 14 filmsko obloženih tablet: EU/1/09/562/002 28 filmsko obloženih tablet: EU/1/09/562/003 30 filmsko obloženih tablet: EU/1/09/562/004 50 filmsko obloženih tablet: EU/1/09/562/005 56 filmsko obloženih tablet: EU/1/09/562/006 84 filmsko obloženih tablet: EU/1/09/562/007 90 filmsko obloženih tablet: EU/1/09/562/008 100 filmsko obloženih tablet: EU/1/09/562/009
The results obtained in populations with different characteristics (e.g. unstable angina or non-Q-wave MI, low to high risk levels, diabetes, need for revascularisation, age, gender, etc.) were consistent with the results of the primary analysis. 
Rezultati, pridobljeni pri populacijah z različnimi karakteristikami (npr. nestabilna angina, MI brez Qzobca, veliko do majhno tveganje, sladkorna bolezen, potreba po revaskularizaciji, spol, starost, itd.), so skladni z rezultati primarne analize.
Cross-reactions among thienopyridines 
Navzkrižne reakcije med tienopiridini
You should not breast-feed while taking this medicine. 
Med jemanjem tega zdravila ne smete dojiti.
The prasugrel-only patients were continued on prasugrel for 11.5 months. 
Bolniki, ki so prejemali le prasugrel, so nadaljevali jemanje prasugrela v obdobju 11,5 meseca.
Clinical trial data support use up to 12 months, and the maximum benefit was seen at 3 months (see section 5.1). 
Podatki iz kliničnih preizkušanj kažejo, da je primerna uporaba do 12 mesecev, največjo korist pa so opazili po 3 mesecih (glejte poglavje 5.1).
Therapeutic experience with clopidogrel is limited in patients with renal impairment. 
Terapevtske izkušnje s klopidogrelom so omejene pri bolnikih z ledvično okvaro.
In addition, a subgroup analysis by age suggested that the benefitof clopidogrel in patients over 75 years was less than that observed in patients ≤75 years. 
Poleg tega analiza podskupin glede na starost nakazuje, da so koristi od zdravljenja s klopidogrelom pri bolnikih, starejših od 75 let, manjše od tistih, ki so jih opazili pri bolnikih starih 75 let ali manj.
Patients who had developed a previous allergic reaction and/or haematological reaction to one thienopyridine may have an increased risk of developing the same or another reaction to another thienopyridine. 
Bolniki, ki so kdaj imeli alergijsko in/ali hematološko reakcijo na enega od tienopiridinov, imajo lahko večje tveganje za pojav enake ali druge reakcije na drug tienopiridin.
The ACTIVE-W and ACTIVE-A studies, separate trials in the ACTIVE program, included patients with atrial fibrillation (AF) who had at least one risk factor for vascular events. 
Študiji ACTIVE-W in ACTIVE-A, ločeni preskušanji v programu ACTIVE, sta vključili bolnike z atrijsko fibrilacijo (AF), ki so imeli vsaj en dejavnik tveganja za žilne dogodke.
The elimination half-life of the main circulating (inactive) metabolite was 8 hours after single and repeated administration. 
Razpolovni čas izločanja glavnega (neaktivnega) krožečega metabolita je bil 8 ur po enkratnem in večkratnem dajanju.
to help prevent blood clots and reduce the risk of these severe events because: - You have a condition of hardening of arteries (also known as atherosclerosis), and - You have previously experienced a heart attack, stroke or have a condition known as peripheral arterial disease. 
vam je predpisano za pomoč pri preprečevanju nastajanja krvnih strdkov in za zmanjšanje tveganja teh hudih dogodkov, ker: - imate otrdele arterije (znano tudi kot ateroskleroza) in - ste predhodno doživeli srčni napad, kap ali imeli stanje, ki je znano kot periferna arterijska bolezen.
plus acetylsalicylic acid if you cannot take ‘oral anticoagulants' and you do not have a risk of major bleeding. 
skupaj z acetilsalicilno kislino, če ne morete prejemati "peroralnih antikoagulantov", ali če nimate tveganja za večjo krvavitev.
There have been a number of retrospective analyses, however, to evaluate this effect in patients treated with clopidogrel for whom there are genotyping results: CURE (n=2721), CHARISMA (n=2428), CLARITY-TIMI 28 (n=227), TRITON-TIMI 38 (n=1477), and ACTIVE-A (n=601), as well as a number of published cohort studies. 
Opravljene pa so bile številne retrospektivne analize za oceno tega učinka pri bolnikih, zdravljenih s klopidogrelom, za katere so na voljo rezultati genotipizacije: CURE (n = 2721), CHARISMA (n = 2428), CLARITY-TIMI 28 (n = 227), TRITON-TIMI 38 (n = 1477) in ACTIVE-A (n = 601), poleg tega pa tudi številne objavljene kohortne študije.
At Day 14, platelet function testing (PFT) was performed. 
Štirinajsti dan so opravili preskušanje funkcije trombocitov (PFT - platelet function testing).
This randomized, open-label trial included 2,610 biomarker-positive ACS patients after successful PCI. 
To randomizirano, odprto preskušanje je vključilo 2.610 bolnikov z AKS in pozitivnimi biološkimi označevalci po uspešni PKI.
Pregnancy and breast-feeding It is preferable not to take this medicine during pregnancy. 
Nosečnost in dojenje Priporočljivo je, da tega zdravila ne jemljejo nosečnice.
per day to be taken orally with or without food, and at the same time each day. 
na dan, ki jo lahko vzamete s hrano ali brez nje; odmerek morate jemati vsak dan ob istem času.
Kounis syndrome (vasospastic allergic angina / allergic myocardial infarction) in the context of a hypersensitivity reaction due to clopidogrel* 
Kounisov sindrom (vazospastična alergijska angina / alergijski miokardni infarkt) v okviru preobčutljivostne reakcije zaradi klopidogrela*
In CAPRIE, in patients treated with either clopidogrel or ASA, the overall incidence of any bleeding was 9.3%. 
V CAPRIE je bila pri bolnikih, zdravljenih bodisi s klopidogrelom ali ASA, celokupna incidenca kakršnihkoli krvavitev 9,3 %.
De-escalation of P2Y12 Inhibitor Agents in ACS 
Deeskalacija zaviralcev P2Y12 pri AKS
is unlikely to affect your ability to drive or to use machines. 
vplivalo na vašo sposobnost za vožnjo ali upravljanje strojev.
In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleeding was low and similar in both groups. 
V študiji COMMIT je bil skupni delež večjih necerebralnih krvavitev ali cerebralne krvavitve nizek in podoben v obeh skupinah.
Less pronounced reductions of metabolite exposure has been observed with pantoprazole or lansoprazole. 
Manj izrazita zmanjšana izpostavljenost presnovkov je bila opažena pri pantoprazolu ali lansoprazolu.
Apart from the specific medicinal product interaction information described above, interaction studies with clopidogrel and some medicinal products commonly administered in patients with atherothrombotic disease have not been performed. 
Razen zgoraj navedenih podatkov o specifičnih interakcijah z zdravili, študij o interakcijah klopidogrela z nekaterimi drugimi zdravili, ki jih bolniki z aterotrombotično boleznijo pogosto uporabljajo, niso izvedli.
Patients with a confirmed diagnosis of acquired haemophilia should be managed and treated by specialists, and clopidogrel should be discontinued. 
Bolnike s potrjeno diagnozo pridobljene hemofilije morajo obravnavati in zdraviti zdravniki specialisti, zdravljenje s klopidogrelom pa je treba prekiniti.
Absorption is at least 50%, based on urinary excretion of clopidogrel metabolites. 
Absorpcija je najmanj 50-odstotna, in to zaradi presnovkov klopidrogela, ki se izločajo z urinom.
You should have been told that ‘oral anticoagulants' are more effective than acetylsalicylic acid or the combined use of Clopidogrel Krka d.d. 
Povedati so vam morali, da so "peroralni antikoagulanti" pri tej motnji učinkovitejši kot acetilsalicilna kislina ali kombinirana uporaba zdravila Clopidogrel Krka d.d.
The binding is non-saturable in vitro over a wide concentration range. 
Pri vezavi in vitro ne pride do nasičenosti v širokem koncentracijskem razponu.
looks like and contents of the pack The film-coated tablets are pink, round and slightly convex. 
in vsebina pakiranja Filmsko obložente tablete so rožnate, okrogle in rahlo izbočene.
After single and repeated oral doses of 75 mg per day, clopidogrel is rapidly absorbed. 
Po enkratnem in večkratnih peroralnih odmerkih po 75 mg na dan se klopidogrel hitro absorbira.
in combination with acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever. 
v kombinaciji z acetilsalicilno kislino, učinkovino, ki je prisotna v številnih zdravilih, ki se uporabljajo za lajšanje bolečine in zniževanje zvišane telesne temperature.
The efficacy of clopidogrel was observed independently of the dose of ASA (75-325 mg once daily). 
Učinkovitost klopidogrela je bila neodvisna od odmerka ASA (75-325 mg enkrat na dan).
The primary endpoint (the combined incidence of CV death, MI, stroke and BARC bleeding grade ≥2 at 12 months) was met showing non-inferiority. 
Primarni opazovani dogodek (kombinirana pojavnost SŽ smrti, MI, možganske kapi in krvavitev ≥ 2 po BARC po 12 mesecih) je bil dosežen in to dokazuje neinferiornost.
The de-escalated patients underwent high platelet reactivity (HPR) testing. 
Bolniki z deeskaliranjem so opravili preskušanje visoke reaktivnosti trombocitov (HPR - high platelet reactivity).
Detailed information is available on the European Medicines Agency website: http://www.ema.europa.eu 
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu/
In CURE, there was no excess in major bleeds with clopidogrel plus ASA within 7 days after coronary bypass graft surgery in patients who stopped therapy more than five days prior to surgery . 
V CURE število velikih krvavitev s klopidogrelom in ASA ni bilo prekoračeno v 7 dneh po koronarni premostitveni operaciji pri bolnikih, ki so prenehali z zdravljenjem več kot 5 dni pred kirurškim posegom.
The patient population included 19.7% women and 29.2% patients ≥ 65 years. 
Populacijo bolnikov je sestavljalo 19,7 % žensk in 29,2 % bolnikov, starih 65 let ali več.
Exposure of clopidogrel and average platelet inhibition can be decreased with concomitant use of ritonavir. 
Izpostavljenost klopidogrelu in povprečno zaviranje trombocitov se lahko ob sočasni uporabi ritonavirja zmanjšata.
Patients were required to have either ECG changes compatible with new ischaemia or elevated cardiac enzymes or troponin I or T to at least twice the upper limit of normal. 
Bolniki so morali imeti bodisi spremembe elektrokardiograma (EKG), združljive z novo ishemijo, ali povišane vrednosti srčnih encimov ali troponina I ali T na nad dvakratno zgornjo mejo normalnega.
Clopidogrel and the main circulating (inactive) metabolite bind reversibly in vitro to human plasma proteins (98% and 94% respectively). 
Klopidogrel in glavni krožeči (neaktivni) presnovek se in vitro reverzibilno vežeta na humane plazemske beljakovine (98- oz. 94-odstotno).
Seventy-three percent (73%) of patients enrolled into the ACTIVE-A study were unable to take VKA due to physician assessment, inability to comply with INR (international normalised ratio) monitoring, predisposition to falling or head trauma, or specific risk of bleeding; for 26% of the patients, the physician's decision was based on the patient's unwillingness to take VKA. 
Triinsedemdeset odstotkov (73 %) bolnikov, vključenih v študijo ACTIVE-A, je bilo neprimernih za prejemanje VKA po zdravnikovi oceni, nezmožnosti upoštevanja kontrol INR (internacionalnega normaliziranega razmerja), nagnjenosti k padcem ali poškodbe glave, ali specifičnega tveganja krvavitev; pri 26 % bolnikov je zdravnikova odločitev temeljila na tem, da bolnik ni želel jemati VKA.
The safety and efficacy of clopidogrel have been evaluated in 5 double-blind studies involving over 88,000 patients: the CAPRIE study, a comparison of clopidogrel to ASA, and the CURE, CLARITY, COMMIT and ACTIVE-A studies comparing clopidogrel to placebo, both medicinal products given in combination with ASA and other standard therapy. 
Varnost in učinkovitost klopidogrela so vrednotili v 5 dvojno slepih študijah, v katere je bilo vključenih več kot 88.000 bolnikov: študija CAPRIE je obsegala primerjavo klopidogrela in ASA, v študijah CURE, CLARITY, COMMIT in ACTIVE-A pa so primerjali klopidogrel s placebom; oboje pa so bolniki dobivali v kombinaciji z ASA in drugo standardno terapijo.
In CURE, CLARITY, ACTIVE-A and one of the cohort studies (Trenk), no increased event rate was observed based on metaboliser status. 
V študijah CURE, CLARITY, ACTIVE-A in eni od kohortnih študij (Trenk) niso odkrili večjega deleža dogodkov glede na metabolizatorsko stanje.
Side effects with frequency not known (frequency cannot be estimated from the available data): Hypersensitivity reactions with chest or abdominal pain, persistent low blood sugar symptoms. 
Neželeni učinki z neznano pogostnostjo (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti): Preobčutljivostne reakcije z bolečinami v prsih ali trebuhu, vztrajajoči znaki nizke vrednosti sladkorja v krvi.
In CURE, 823 (6.6%) patients received concomitant GPIIb/IIIa receptor antagonist therapy. 
V študiji CURE je 823 (6,6 %) bolnikov sočasno jemalo antagoniste receptorja glikoproteina IIb/IIIa.
Data from the CAPRIE study indicate that phenytoin and tolbutamide which are metabolised by CYP2C9 can be safely co-administered with clopidogrel. 
Podatki študije CAPRIE kažejo, da se lahko fenitoin in tolbutamid, ki se presnavljata s CYP2C9, sočasno s klopidogrelom varno uporabljata.
Warnings and precautions If any of the situations mentioned below apply to you, you should tell your doctor before taking Clopidogrel Krka d.d. 
Opozorila in previdnostni ukrepi Če katerokoli od spodaj navedenih stanj velja za vas, morate o tem obvestiti svojega zdravnika, preden boste vzeli zdravilo Clopidogrel Krka d.d.
Although the clinical relevance of these findings is uncertain, there have been spontaneous reports of HIV-infected patients treated with boosted ART, who have experienced reocclusive events after de-obstruction or have suffered thrombotic events under a clopidogrel loading treatment schedule. 
Čeprav je klinični pomen teh opažanj negotov, obstajajo sponatna poročila o bolnikih, okuženih z virusom HIV, zdravljenih z okrepljenim protiretrovirusnim zdravljenjem, ki so doživeli ponovne okluzivne dogodke po odpravi obstrukcije ali so doživeli trombotične dogodke med zdravljenjem s polnilnim odmerkom klopidogrela.
The population included 27.8% women, 58.4% patients ≥ 60 years (26% ≥ 70 years) and 54.5% patients who received fibrinolytics. 
Populacijo bolnikov je sestavljalo 27,8 % žensk, 58,4 % bolnikov, starih 60 let ali več (26 % ≥ 70 let), in 54,5 % bolnikov, ki so dobivali fibrinolitike.
Bleeding time prolonged, neutrophil count decreased, platelet count decreased * Information related to clopidogrel with frequency “not known”. 
Preiskave podaljšan čas krvavitve, zmanjšano število nevtrofilcev, zmanjšano število trombocitov * Podatki se nanašajo na klopidogrel s pogostnostjo “neznani”.